MX2021009761A - Compuesto de pirimidinil-3,8-diazabiciclo [3.2.1]octanilmetanona cristalina y uso de este. - Google Patents

Compuesto de pirimidinil-3,8-diazabiciclo [3.2.1]octanilmetanona cristalina y uso de este.

Info

Publication number
MX2021009761A
MX2021009761A MX2021009761A MX2021009761A MX2021009761A MX 2021009761 A MX2021009761 A MX 2021009761A MX 2021009761 A MX2021009761 A MX 2021009761A MX 2021009761 A MX2021009761 A MX 2021009761A MX 2021009761 A MX2021009761 A MX 2021009761A
Authority
MX
Mexico
Prior art keywords
diazabicyclo
octanylmethanone
pyrimidinyl
crystalline
compound
Prior art date
Application number
MX2021009761A
Other languages
English (en)
Spanish (es)
Inventor
Xiaojing Yang
Amanda Patrice Surajhie Samuel
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2021009761A publication Critical patent/MX2021009761A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
MX2021009761A 2019-02-15 2020-02-12 Compuesto de pirimidinil-3,8-diazabiciclo [3.2.1]octanilmetanona cristalina y uso de este. MX2021009761A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806180P 2019-02-15 2019-02-15
PCT/IB2020/051128 WO2020165788A1 (en) 2019-02-15 2020-02-12 Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof

Publications (1)

Publication Number Publication Date
MX2021009761A true MX2021009761A (es) 2021-12-15

Family

ID=69726639

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009761A MX2021009761A (es) 2019-02-15 2020-02-12 Compuesto de pirimidinil-3,8-diazabiciclo [3.2.1]octanilmetanona cristalina y uso de este.

Country Status (15)

Country Link
US (2) US12312358B2 (cg-RX-API-DMAC7.html)
EP (1) EP3924355B1 (cg-RX-API-DMAC7.html)
JP (1) JP7561497B2 (cg-RX-API-DMAC7.html)
KR (2) KR102820235B1 (cg-RX-API-DMAC7.html)
CN (1) CN113646310A (cg-RX-API-DMAC7.html)
AR (1) AR118099A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020222083B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015951A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130034C (cg-RX-API-DMAC7.html)
ES (1) ES3065864T3 (cg-RX-API-DMAC7.html)
MX (1) MX2021009761A (cg-RX-API-DMAC7.html)
SG (1) SG11202108863WA (cg-RX-API-DMAC7.html)
TW (1) TWI820301B (cg-RX-API-DMAC7.html)
WO (1) WO2020165788A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202106815B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102820235B1 (ko) * 2019-02-15 2025-06-16 화이자 인코포레이티드 결정질 피리미디닐-3,8-다이아자바이사이클로[3.2.1]옥타닐메타논 화합물 및 이의 용도
US12673955B2 (en) 2020-06-09 2026-07-07 Crystal Pharmatech Co., Ltd. Crystal form of p-toluenesulfonate salt of diazabicyclic compound and preparation method therefor
CN114835717A (zh) * 2021-02-01 2022-08-02 杭州领业医药科技有限公司 Brepocitinib甲苯磺酸盐的晶型及其制备方法和用途
CN113461687B (zh) * 2021-08-10 2022-04-19 四川大学华西医院 2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5023556A (en) 1990-02-02 1991-06-11 Conax Florida Corporation Sensor circuit response to different fluid conductivities and having time delay feature
EA027879B1 (ru) 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
NO2721710T3 (cg-RX-API-DMAC7.html) 2014-08-21 2018-03-31
KR20260080448A (ko) * 2018-03-30 2026-06-02 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
KR102820235B1 (ko) * 2019-02-15 2025-06-16 화이자 인코포레이티드 결정질 피리미디닐-3,8-다이아자바이사이클로[3.2.1]옥타닐메타논 화합물 및 이의 용도

Also Published As

Publication number Publication date
TWI820301B (zh) 2023-11-01
CA3130034C (en) 2023-12-19
US20220144846A1 (en) 2022-05-12
ZA202106815B (en) 2026-03-25
JP2020138960A (ja) 2020-09-03
EP3924355B1 (en) 2025-12-31
KR102820235B1 (ko) 2025-06-16
SG11202108863WA (en) 2021-09-29
AU2020222083A1 (en) 2021-09-02
EP3924355A1 (en) 2021-12-22
EP3924355C0 (en) 2025-12-31
JP7561497B2 (ja) 2024-10-04
KR20240116855A (ko) 2024-07-30
ES3065864T3 (en) 2026-05-08
CA3130034A1 (en) 2020-08-20
AU2020222083B2 (en) 2022-11-17
AR118099A1 (es) 2021-09-15
US20250282789A1 (en) 2025-09-11
US12312358B2 (en) 2025-05-27
TW202045511A (zh) 2020-12-16
CN113646310A (zh) 2021-11-12
BR112021015951A2 (pt) 2021-10-05
KR20210114470A (ko) 2021-09-23
WO2020165788A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
ZA202106815B (en) Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
CR20200621A (es) Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
ZA202007671B (en) Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof
BR112022005193A2 (pt) Composto de piridona fundido, método de preparação do mesmo e uso do mesmo
MX2021003241A (es) Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo.
ECSP109979A (es) Preparación sólida que contiene alogliptina y clorhidrato de metformina
ECSP17046065A (es) Formas cristalinas de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenolhidrocloruro (solicitud divisional)
UY27740A1 (es) Nuevos compuestos
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
MX2019011904A (es) Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos.
MX391567B (es) Agentes de imagenología nuevos para tomografía de emisión de positrones (pet) sustituidos con deuterio y su aplicación farmacológica.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
BRPI0518360A2 (pt) composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
BR112022010377A2 (pt) Novos tiromiméticos
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
MX2020007271A (es) Sales y cristales novedosos.
BRPI0804091B8 (pt) compostos de 1,2,4,5-tetrahidro-3h-benzazepina, processo para sua preparação e composições farmacêuticas que os contêm
EA200900959A1 (ru) Ингибиторы мек
MX2022004686A (es) Composiciones farmaceuticas que comprenden (s)-2-(2,6-dioxopiperid in-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1- il)metil)bencil)indolin-1,3-diona y metodos de uso de las mismas.
PH12022550531A1 (en) Irak inhibitor and preparation method therefor and use thereof
SE0302546D0 (sv) New compounds
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
EP3880671C0 (en) NOVEL COMPOUND USED AS A PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME